A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy
Open Access
- 3 November 2008
- Vol. 113 (10) , 2742-2751
Abstract
BACKGROUND.: Advanced hepatocellular carcinoma (HCC) patients who are not candidates for surgery or locoregional therapy are the focus of clinical trials of systemic therapy, as their overall prognosis remains poor. However, the current prognostic systems cannot reliably select appropriate candidates for systemic therapy trials based on the probability of 3‐month survival. In this study, the authors constructed a new prognostic score system, the Advanced Liver Cancer Prognostic System (ALCPS), which can objectively predict the probability of 3‐month survival.METHODS.: Between 1990 and 2005, 1470 patients with advanced HCC who were not amendable to surgery or locoregional therapy were included in the analysis. The prognostic score system was developed from the multivariate Cox model through a point system and validated in an independent set. Okuda staging and Cancer of the Liver Italian Program (CLIP) score were also applied to the validation set to compare their predictive accuracy.RESULTS.: The ALCPS was based on 11 prognostic factors with different weights: ascites, abdominal pain, weight loss, Child‐Pugh grade, alkaline phosphatase, total bilirubin, alpha‐fetal protein, urea, portal vein thrombosis, tumor size, and presence of lung metastases. It stratified patients in both training and validation sets to different prognostic groups with significant difference in 3‐month overall survival (P < .0001). By using the patients in the validation set with known 3‐month survival status, the ALCPS showed significantly better predictive power (area under the curve [AUC], 0.77) than Okuda score (AUC, 0.66; P < .001) and CLIP score (AUC, 0.71; P = .002).CONCLUSIONS.: The new prognostic system can objectively help the clinicians to select appropriate candidates for evaluation of treatment efficacy in systemic therapy trials for advanced HCC. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 17 references indexed in Scilit:
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?The Oncologist, 2006
- Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2005
- Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular CancerJournal of Clinical Oncology, 2005
- Presentation of multivariate data for clinical use: The Framingham Study risk score functionsStatistics in Medicine, 2004
- Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging systemCancer, 2002
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999
- A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patientsHepatology, 1998
- Checking the Cox model with cumulative sums of martingale-based residualsBiometrika, 1993